GSK and iTeos drop anti-TIGIT drug following trial failure

This follows what appeared to be a generally positive data readout for belrestotug at ESMO 2024 just a few months ago.

Related Posts

FDA lifts two-year clinical hold on CytoDyn’s HIV trial

Mar 1, 2024

Magazine: Lula’s progress plan for Brazil: a year on

May 25, 2024

Lenvatinib mesylate by Eisai for Metastatic Biliary Tra...

Dec 24, 2023